Italfarmaco has announced results for their Givinostat trial in Becker muscle dystrophy (BMD). Although the change in total fibrosis in muscle biopsy did not show a significant difference in 51 adult males with BMD, it did show a significant difference from placebo on muscle MRI confirming the ability of Givinostat to counteract muscle deterioration. Italfarmaco plans to speak with regulators to continue this program development.
Italfarmaco: Topline Data from Phase 2 Trial with Givinostat
July 2, 2021